PMV Pharmaceuticals (NASDAQ:PMVP) Trading 1.4% Higher

PMV Pharmaceuticals, Inc. (NASDAQ:PMVPGet Rating) shares traded up 1.4% during trading on Friday . The company traded as high as $11.85 and last traded at $11.85. 922 shares traded hands during trading, a decline of 100% from the average session volume of 770,847 shares. The stock had previously closed at $11.69.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price target on shares of PMV Pharmaceuticals in a research report on Wednesday, June 8th. Oppenheimer lifted their price target on PMV Pharmaceuticals from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, June 9th.

PMV Pharmaceuticals Stock Performance

The stock has a 50 day simple moving average of $14.48 and a two-hundred day simple moving average of $15.27. The firm has a market cap of $524.63 million, a PE ratio of -7.51 and a beta of 1.13.

Hedge Funds Weigh In On PMV Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Virtus ETF Advisers LLC increased its stake in shares of PMV Pharmaceuticals by 14.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,151 shares of the company’s stock valued at $165,000 after purchasing an additional 922 shares in the last quarter. Legal & General Group Plc increased its stake in shares of PMV Pharmaceuticals by 14.9% in the 2nd quarter. Legal & General Group Plc now owns 8,122 shares of the company’s stock valued at $116,000 after purchasing an additional 1,055 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of PMV Pharmaceuticals by 7.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 15,613 shares of the company’s stock valued at $222,000 after purchasing an additional 1,109 shares in the last quarter. Nisa Investment Advisors LLC purchased a new position in shares of PMV Pharmaceuticals in the 1st quarter valued at about $25,000. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of PMV Pharmaceuticals by 10.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 17,600 shares of the company’s stock valued at $379,000 after purchasing an additional 1,600 shares in the last quarter.

PMV Pharmaceuticals Company Profile

(Get Rating)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.

See Also

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.